Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.

Antimicrobial Agents and Chemotherapy
Stefanie HenkenUlrich A Maus

Abstract

Daptomycin is a novel lipopeptide antibiotic with excellent activity against Gram-positive bacterial pathogens, but its therapeutic value for the treatment of invasive pneumococcal disease compared to that for the treatment of pneumococcal pneumonia is incompletely defined. We investigated the efficacy of daptomycin in two models of Streptococcus pneumoniae-induced lung infection, i.e., pneumococcal pneumonia and septic pneumococcal disease. Mice were infected with a bioluminescent, invasive serotype 2 S. pneumoniae strain or a less virulent serotype 19 S. pneumoniae strain and were then given semitherapeutic or therapeutic daptomycin or ceftriaxone. Readouts included survival; bacterial loads; and septic disease progression, as determined by biophotonic imaging. Semitherapeutic daptomycin treatment fully protected the mice against the progression of septic disease induced by serotype 2 S. pneumoniae, while therapeutic treatment of the mice with daptomycin or ceftriaxone led to approximately 70% or approximately 60% survival, respectively. In contrast, mice infected with serotype 19 S. pneumoniae developed severe pneumonia and lung leakage even in the presence of increased intra-alveolar daptomycin levels, resulting in only 40%...Continue Reading

References

Oct 6, 2000·The Journal of Antimicrobial Chemotherapy·F P Tally, M F DeBruin
May 17, 2001·Antimicrobial Agents and Chemotherapy·J A SilvermanT Li
May 17, 2001·Antimicrobial Agents and Chemotherapy·A L BarryS D Brown
May 11, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·Ulrich A MausJürgen Lohmeyer
Aug 3, 2002·American Journal of Respiratory and Critical Care Medicine·Ulrich MausJürgen Lohmeyer
Mar 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ulrich A MausJürgen Lohmeyer
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Jared A SilvermanHoward M Shapiro
Jul 31, 2003·The Journal of Antimicrobial Chemotherapy·Habib M AlloushAlasdair P MacGowan
Nov 19, 2003·Scandinavian Journal of Infectious Diseases·Carlos J OrihuelaElaine Tuomanen
Mar 24, 2004·Trends in Immunology·Aras Kadioglu, Peter W Andrew
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
May 18, 2005·The Journal of Infectious Diseases·Jared A SilvermanJeff Alder
Jul 5, 2005·Expert Opinion on Investigational Drugs·F P TallyF B Oleson
Jun 8, 2006·Journal of Clinical Microbiology·James H Jorgensen, Sharon A Crawford
Feb 27, 2007·American Journal of Respiratory and Critical Care Medicine·Ulrich A MausKlaus T Preissner
Apr 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christine WinterUlrich A Maus
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christine WinterUlrich A Maus
Oct 18, 2007·Pharmacology·Robert SauermannChristian Joukhadar
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter E PertelJeff Alder
Oct 8, 2008·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jens Martens-LobenhofferStefanie M Bode-Böger
Dec 31, 2008·The Journal of Infectious Diseases·Asa KarlströmJonathan A McCullers
Mar 24, 2009·Current Opinion in Chemical Biology·Richard H Baltz
Apr 4, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christine WinterUlrich A Maus
Apr 25, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R R Reinert

❮ Previous
Next ❯

Citations

Sep 3, 2013·International Journal of Antimicrobial Agents·Jacques VouillamozGrégory Resch
Dec 24, 2010·American Journal of Respiratory Cell and Molecular Biology·Ines HahnUlrich A Maus
Mar 6, 2013·Expert Review of Anti-infective Therapy·Isabella KanzlerAndres Beiras-Fernandez
Jul 9, 2013·Expert Opinion on Drug Discovery·Michio KurosuKatsuhiko Mitachi
Dec 2, 2014·Respiratory Medicine·Tobias Welte
Oct 8, 2016·Annals of Intensive Care·Gabor ZilahiIgnacio Martin-Loeches
Oct 5, 2013·Clinical Microbiology Reviews·Romney M HumphriesGeorge Sakoulas
Aug 31, 2019·International Journal of Molecular Sciences·Noemi BorsaMarcos I Restrepo
Mar 15, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Martina WeberMichael Bauer
Oct 18, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kathrin SteinwedeUlrich A Maus
Sep 5, 2014·Current Opinion in Critical Care·Ignacio Martín-LoechesJordi Vallés
Jan 4, 2020·The European Respiratory Journal·Carlos J OrihuelaJeremy S Brown
Sep 2, 2020·Pharmaceuticals·Foteini TsakouBiljana Mojsoska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.